

IV. 研究成果の刊行物・別刷

RESEARCH PAPER

Necklace cytoplasmic bodies in hereditary myopathy with early respiratory failure

Akinori Uruha,^{1,2,3} Yukiko K Hayashi,^{1,2,4} Yasushi Oya,⁵ Madoka Mori-Yoshimura,⁵ Masahiro Kanai,⁵ Miho Murata,⁵ Mayumi Kawamura,⁶ Katsuhisa Ogata,⁷ Tsuyoshi Matsumura,⁸ Shigeaki Suzuki,⁹ Yukako Takahashi,^{10,11} Takayuki Kondo,¹¹ Takeshi Kawarabayashi,¹² Yuko Ishii,¹³ Norito Kokubun,¹³ Satoshi Yokoi,¹⁴ Rei Yasuda,¹⁵ Jun-ichi Kira,¹⁶ Satomi Mitsuhashi,^{1,2} Satoru Noguchi,^{1,2} Ikuya Nonaka,^{2,7} Ichizo Nishino^{1,2}

► Additional material is published online only. To view please visit the journal online (<http://dx.doi.org/10.1136/jnnp-2014-309009>).

For numbered affiliations see end of article.

Correspondence to

Dr Ichizo Nishino, Department of Neuromuscular Research, National Institute of Neuroscience, NCNP, 4-1-1 Ogawa-Higashi, Kodaira, Tokyo 187-8502, Japan; nishino@ncnp.go.jp

Received 15 July 2014

Revised 2 September 2014

Accepted 7 September 2014

ABSTRACT

Background In hereditary myopathy with early respiratory failure (HMERF), cytoplasmic bodies (CBs) are often localised in subsarcolemmal regions, with necklace-like alignment (necklace CBs), in muscle fibres although their sensitivity and specificity are unknown.

Objective To elucidate the diagnostic value of the necklace CBs in the pathological diagnosis of HMERF among myofibrillar myopathies (MFMs).

Methods We sequenced the exon 343 of *TTN* gene (based on ENST00000589042), which encodes the fibronectin-3 (FN3) 119 domain of the A-band and is a mutational hot spot for HMERF, in genomic DNA from 187 patients from 175 unrelated families who were pathologically diagnosed as MFM. We assessed the sensitivity and specificity of the necklace CBs for HMERF by re-evaluating the muscle pathology of our patients with MFM.

Results *TTN* mutations were identified in 17 patients from 14 families, whose phenotypes were consistent with HMERF. Among them, 14 patients had necklace CBs. In contrast, none of other patients with MFM had necklace CBs except for one patient with reducing body myopathy. The sensitivity and specificity were 82% and 99%, respectively. Positive predictive value was 93% in the MFM cohort.

Conclusions The necklace CB is a useful diagnostic marker for HMERF. When muscle pathology shows necklace CBs, sequencing the FN3 119 domain of A-band in *TTN* should be considered.

INTRODUCTION

Hereditary myopathy with early respiratory failure (HMERF; OMIM 603689) is an adult-onset progressive myopathy characterised by early presentation of respiratory insufficiency usually during ambulant stage.¹⁻³ Pathologically, HMERF shares features of myofibrillar myopathy (MFM) besides the key finding of cytoplasmic bodies (CBs).^{2,3} Its causative gene *TTN*, which encodes a gigantic protein, titin,^{2,3} is known to be causative also for tibial muscular dystrophy, limb girdle muscular dystrophy type 2J, early-onset myopathy with fatal cardiomyopathy and dilated or hypertrophic cardiomyopathy.⁴⁻¹⁰ Interestingly, all patients with HMERF so far identified carry a mutation in exon

343 (based on ENST00000589042) encoding the fibronectin-3 (FN3) 119 domain in the A-band region of titin.^{2,3,11-17}

CBs are abnormal protein aggregates visualised usually as red-colored objects on modified Gomori trichrome stain and can be observed in a wide range of myopathic conditions. Nevertheless, they are often conspicuous in MFM and considered as one of the representative pathological findings in MFM.¹⁸ In muscle specimens of HMERF, CBs are often located in the subsarcolemmal region,^{12,13,14,19} with a necklace-like alignment, which here we call 'necklace CBs'. However, the utility of necklace CBs in the pathological diagnosis of HMERF is unknown. We therefore tested the sensitivity and specificity of necklace CBs in the diagnosis of HMERF.

METHODS**Patients**

National Center of Neurology and Psychiatry (NCNP) functions as a referral centre for muscle pathology and muscle biopsy samples are sent from all over Japan. From 1991 to 2013, 187 patients from unrelated 175 Japanese families have been pathologically diagnosed as MFM at NCNP. In this cohort, mutations were found in known MFM-related genes: *DES*: 8 families (4.6%), *VCP*: 8 families (4.6%), *FLNC*: 6 families (3.4%), *DNAJB6*: 6 families (3.4%), *ZASP*: 5 families (2.9%), *FHL1*: 5 families (2.9%), *MYOT*: 4 families (2.3%) and *BAG3*: 1 family (0.6%). No mutation was identified in *CRYAB*. Clinical information at the time of muscle biopsy was available in all patients.

Genetic analysis

Genomic DNA was isolated from peripheral lymphocytes or frozen muscle as previously described.²⁰ Exon 343 of *TTN* was directly sequenced using ABI PRISM 3130 automated sequencer (PE Applied Biosystems). Sequence variants were assessed using publicly available databases including 1000 Genomes Project database (<http://www.1000genomes.org/>), NHLBI Exome Sequencing Project 5400 database (<http://evs.gs.washington.edu/EVS/>), dbSNP135 (<http://www.ncbi.nlm.nih.gov/SNP/>) and Human Genetic Variation Browser (<http://www.genome.med.kyoto-u.ac.jp/SnpDB/>); and

To cite: Uruha A, Hayashi YK, Oya Y, et al. *J Neurol Neurosurg Psychiatry* Published Online First: [please include Day Month Year] doi:10.1136/jnnp-2014-309009

Table 1 Clinical features of the patients with *TTN* variants

Patient Number	Age (years)/sex	Relationship	Mutation (protein level)	Family history (years)	Initial manifestations (years)	Age at gait disturbance/ambulant	Foot drop (years)	Respiratory disturbance (years)	Artificial ventilation (years)	Cardiac involvement	Dysphagia (years)	Other features
A-1	49/M	Father	p.C31712R		Tripping (46)	46/yes	Yes (NA)	Yes (48)	Yes (49)	RHF	No	No
A-2	26/M	Son			Tripping (20)	22/yes	Yes (22)	Yes*	No	No	No	No
B-1	45/M	Older brother	p.C31712R	Father: Foot drop;	Foot drop (31)	31/yes	Yes (31)	Yes (44)	Yes (45)	No	No	No
B-2	37/M	Younger brother		sudden death (42) Oldest brother: gait disturbance (32); sudden death (40)	Foot drop (27)	27/yes	Yes (27)	Yes (34)	Yes (37)	No	No	No
C	34/F		p.C31712R		Fatiguability (26)	29/yes	Yes (31)	Yes (26)	Yes (31)	–	No	Difficulty in opening mouth
D	38/M		p.C31712R		Difficulty in lifting thigh (20)	20/no (32)	Yes (20 s)	Yes (29)	Yes (29)	STC	Yes (28) Artificial nutrition (35)	
E	40/M		p.C31712R	Mother: sudden death (38) Older sister: proximal muscle weakness; respiratory failure (35)	Fatiguability; respiratory failure (31)	31/yes	Yes (NA)	Yes (31)	Yes (37)	RHF, PH	–	
F	52/M		p.C31712R		Foot drop (47)	47/yes	Yes (47)	Yes (50)	Yes (52)	–	Yes (47)	
G-1	58/M	Father	p.C31712R	Grandfather of G-2: died of respiratory failure (45)	Tripping (57)	57/yes	Yes (58)	Yes*	–	–	–	
G-2	29/M	Son			Tripping (20)	20/yes	Yes (20 s)	Yes (29)	Yes (29)	RHF	–	
H	68/F		p.C31712R	Son: distal myopathy; sudden death	Difficulty in standing on right toe (56)	56/yes	No	Yes (68)	Yes (68)	RHF, Af	–	Head drop; forward bent posture
I	43/M		p.C31712R		Fatiguability; weight loss (39)	42/yes	No	Yes (39)	Yes (42)	–	Yes (42)	Myalgia muscle cramp
J	42/F		p.C31712Y		Difficulty lifting thighs (36)	38/yes	No	Yes*	–	–	–	
K	38/M		p.G31791D		Gait disturbance (28)	28/yes	Yes (30)	Yes*	Yes (38)	–	Yes (36)	Head drop
L	44/F		p.G31791R		Fatiguability; loss of appetite (40)	41/yes	No	Yes (40)	Yes (44)	STC	–	
M	40/M		p.G31791V	Mother and younger sister: lower leg muscle weakness	Gait disturbance (24)	24/yes	Yes (27)	Yes*	–	2° AVB (type 1)	–	
N	46/M		p.R31783_V31785del		Foot drop; difficulty in opening a bottle (41)	41/yes	Yes (41)	Yes*	–	–	–	Myalgia

*Asymptomatic but found by laboratory tests.

2° AVB (type 1), Mobitz type 1 second degree atrioventricular block; Af, atrial fibrillation; F, female; M, male; NA, not available; PH, pulmonary hypertension; RHF, right-sided heart failure; STC, sinus tachycardia.

softwares to predict functional effects of mutations such as PolyPhen-2 (<http://genetics.bwh.harvard.edu/pph2/>) and Mutation Taster (<http://www.mutationtaster.org/>). The description of mutations of *TTN* conforms to Ensemble sequence ENST00000589042.

In this study a diagnosis of HMERF was made based on the presence of a mutation in exon 343 of *TTN*, although the possibility that mutations in other parts of the gene cause HMERF cannot be totally excluded.

Re-evaluation of muscle pathology

Muscle pathology was re-evaluated focusing on necklace CBs on modified Gomori trichrome. In the present study, we tentatively defined the presence of necklace CBs as at least two muscle fibres containing CBs exclusively localised in the subsarcolemmal area, covering more than 50% of circumference of each muscle fibre in three non-serial sections (each section was at least 250 µm apart and included at least 300 muscle fibres). CBs were evaluated in all MFM cases, and subsequently the sensitivity and specificity of necklace CBs for the diagnosis of HMERF were calculated. The positive predictive value (PPV) and 95% CIs were calculated with GraphPad Prism V.5.0 (Graph Pad Software, California, USA).

Electron microscopic observation

Biopsied muscle specimens were fixed in 2.5% glutaraldehyde and post-fixed with 2% osmium tetroxide. Semithin sections stained with toluidine blue were examined by light microscopy. Ultrastructural analysis was carried out on longitudinal and transverse ultrathin sections of muscles after staining with uranyl acetate and lead citrate, using Tecnai spirit transmission electron microscope (FEI, Hillsboro, Oregon, USA).

Re-evaluation of clinical data

The clinical information in our cohort together with previous reports^{2 3 11-14} showed that respiratory insufficiency before being wheelchair users and selective involvement of semitendinosus muscles on muscle imaging were frequently observed, raising a possibility that these findings might be clues for the diagnosis of HMERF. We therefore reviewed clinical data of our patients with MFM in order to calculate sensitivities, specificities and PPVs of them at the time of muscle biopsy.

Ethics

All of the clinical information and materials used in this study were obtained for diagnostic purpose and permitted for scientific use with written informed consent. All experiments in this study were approved by the Ethical Committee of National Center of Neurology and Psychiatry.

RESULTS

Mutation analysis

Six different heterozygous mutations in exon 343 of *TTN* were identified in 17 patients from 14 families (table 1). Among them, two mutations, g.284701T>C (c.95134T>C; p.C31712R) and g.284939G>A (c.95372G>A; p.G31791D) were previously reported.^{2 3 11 12 14} The former mutation was reported to be the most common in other populations.^{11 12} This was also the case in our cohort and the mutation was shared by nine families, while all others were found in single families. The latter mutation was previously reported in a European-American family.¹⁴ Among four novel mutations that we identified, three were missense: g.284702G>A (c.95135G>A; p.C31712Y), g.284938G>C (c.95371G>C; p.G31791R) and g.284939G>T (c.95372G>T; p.G31791V); and one was non-frameshift deletion: g.284913_284921delGAGGGCAGT (c.95346_95354del; p.R31783_V31785del). None of the variants was listed in the

Table 2 Laboratory findings at the time of muscle biopsy

Patient	CK IU/L (normal value)	Respiratory function (%VC, sitting position)	Selective involvement of muscles on imaging test		Muscle pathology		
			Semitendinosus muscle	Anterior compartment of lower legs	CB	Necklaces of CBs	RV
A-1 (49 years)	Normal (value: NA)	Abnormal (value: NA.)	NA	NA	+	+	+
A-2 (26 years)	65 (20–190)	77% (68%, lying)	+	+	+	+	+
B-1 (39 years)	425 (51–197)	84% → 67% (45 years)	+	+	+	+	–
B-2 (32 years)	659 (–200)	82% → 63% (37 years)	+	+	+	+	+
C (31 years)	488 (45–170)	32%	NA (+, 34 years)	NA (+, 34 years)	+	+	–
D (31 years)	375 (51–197)	VC: 0.97 L	+	–*	+	+	–
E (40 years)	234 (62–287)	ABG: PaCO ₂ 86 mm Hg, PaO ₂ 56 mm Hg (RA)	+	+	+	+	–
F (50 years)	61 (NA)	41%	+	+	+	–	–
G-1 (58 years)	146 (50–170)	59%	+	+	+	–	–
G-2 (29 years)	142 (50–170)	31%	+	+	+	+	+
H (68 years)	140 (50–170)	ABG: PaCO ₂ 60 mm Hg	+	+	+	+	–
I (43 years)	179 (62–287)	40%	+	+	+	–	–
J (42 years)	364 (45–163)	64%	+	+	+	+	+
K (34 years)	645 (51–197)	67% (55%, lying)	+	+	+	+	+
L (44 years)	139 (43–165)	36%	+	+	+	+	–
M (40 years)	190 (62–287)	61%	–*	+	+	+	+
N (46 years)	799 (62–287)	67%	+	+	+	+	+

In the column of Patient, the same alphabet indicates that they belong to the same family.

*Diffuse muscle involvement.

ABG, arterial blood gas; CB, cytoplasmic body; NA, not available; RV, rimmed vacuole; VC, vital capacity.

Neuromuscular




Figure 1 Necklace cytoplasmic bodies. Cytoplasmic bodies are located in line in subsarcolemmal region, often covering the total circumference of a muscle fibre. Modified Gomori trichrome stain. Bar: 50 μ m.

genomic variation databases. The mutated amino acids were highly conserved among species (UCSC Genome Browser). PolyPhen-2 predicted p.C31712Y, p.G31791R and p.G31791V mutations as probably damaging with scores 0.996, 1.000 and 1.000, respectively. Likewise, Mutation Taster predicted the p.C31712Y, p.G31791R, p.G31791V and p.V31782_A31784del mutations to be disease-causing with a probability of 1.000, 1.000, 1.000 and 0.998, respectively. No segregation analysis was possible in any family.

Clinical information of 17 participants with *TTN* mutations are summarised in tables 1 and 2 and online supplementary table. All patients show clinical signs consistent with HMERF previously reported.^{1-3 11-14} The median age of onset was

Table 3 Cross tabulation of necklace cytoplasmic bodies and hereditary myopathy with early respiratory failure

Necklace CBs	Patients with myofibrillar myopathies		Row total
	HMERF	Non-HMERF	
+	14	1	15
% within column	82.4%	0.6%	
% within row	93.3%	6.7%	
-	3	169	172
% within column	17.6%	99.4%	
% within row	1.7%	98.3%	
Column total	17	170	187

CB, cytoplasmic body; HMERF, hereditary myopathy with early respiratory failure.

31 years (range 20–57 years). Four patients developed dysphagia, and one of them required tube feeding.

Sensitivity and specificity of the necklace of CBs

Among 17 genetically-confirmed patients with HMERF, necklace CBs were found in 14 patients, comprising 0.1–0.8% of the muscle fibres (figure 1). In contrast, none of the 170 patients who had MFM other than HMERF had necklace CBs except for only one patient who had reducing body myopathy, which had been confirmed by the presence of reducing bodies in muscle fibres on menadione-linked α -glycerophosphate dehydrogenase (MAG) stain without substrate and a mutation in the second LIM domain of *FHL1* (g.60438G>A; c.377G>A; p.C126Y, based on ENST00000543669; online supplementary figure S1). Based on these results, the sensitivity and specificity of the necklace CBs in HMERF were calculated as 82% (14/17, 95% CI 57% to 96%) and 99% (169/170, 95% CI 97% to 100%), respectively (table 3). Since the prevalence of HMERF in the MFM cohort was 9.1% (17/187), the PPV was calculated as 93% (95% CI 68% to 100%) based on Bayes' theorem.




Figure 2 Electron microscope images. (A and B) Sarcomeric disarrangement limited to one sarcomere is observed. (C) Multiple electron-dense inclusions are present in association with Z lines. (D) A fibre containing necklace cytoplasmic bodies (CBs) shows marked myofibrillar disorganisation (asterisk), especially around the CBs. (E) CBs showing a necklace alignment with lower electron density as compared to that of Z line. Δ : a remnant of Z line. (F) Thin filamentous structure around the CBs. Lattice-like structure is not seen in the CBs. Bar: 0.5 μ m (A, B and F), 1 μ m (E), 2 μ m (C), and 5 μ m (D).

Muscle specimens of the three patients with HMREF had CBs, which are usually located in the subsarcolemmal regions, but did not show the definite necklace-like alignment pattern (online supplementary figure S2). Those three patients shared the same mutation, g.284701T>C (p.C31712R), albeit other nine patients harbouring the same mutation had definite necklace CBs.

Fibres with rimmed vacuoles were occasionally seen, but the sensitivity, specificity and PPV for HMREF were lower than those of the necklace CBs: 47% (8/ 17, 95% CI 23% to 72%), 61% (104/ 170, 95% CI 53% to 69%) and 11% (95% CI 20% to 48%), respectively.

Ultrastructural features

EM samples were available from four patients with HMREF. Sarcomeric disarrangement limited to one sarcomere was observed in all patients (figure 2A, B). In some areas, multiple electron-dense inclusions associated with Z line were surrounded by disorganised myofibrils (figure 2C). Fibres with necklace CBs were included only in one sample. These fibres showed marked myofibrillar disorganisation (figure 2D, asterisk), especially in the vicinity of the CBs (figure 2D, E). The CBs had a lower electron density as compared with that of the Z line and contained dense and mildly filamentous components, without lattice-like structure (figure 2E, F). Small number of CBs were partly surrounded by thin filaments (figure 2F).

Sensitivity and specificity of respiratory dysfunction and muscle imaging data

Using the data at the time of muscle biopsy about the respiratory function of 102 participants in the MFM cohort, the sensitivity, specificity and PPV of the respiratory insufficiency before being wheelchair users (below 80% of vital capacity or over 45 mm Hg of PaCO₂) were calculated as 88% (14/16, 95% CI 62% to 99%), 94% (81/86, 95% CI 87% to 98%) and 74% (95% CI 49% to 91%), respectively (table 2 and 4). In five non-HMREF participants presenting respiratory insufficiency during the ambulant stage, one had a mutation in *VCP*, but no causative genes were identified in four participants as far as we have screened.

As for the muscle imaging at the time of muscle biopsy, the sensitivity of selective muscle involvement of semitendinosus muscles as shown in figure 3 was 93% (14/ 15; table 4). The specificity could not be calculated due to the limited number of images available in non-HMREF participants.




Figure 3 Muscle image. Representative image showing preferential involvement of semitendinosus muscles. CT images of skeletal muscles in proximal legs of the patient K. Δ : semitendinosus muscles.

DISCUSSION

We have demonstrated that necklace CBs had high specificity for a diagnosis of HMREF (99%), with sensitivity 82% and PPV 93% in our MFM cohort. In this study, all 15 patients with necklace CBs had HMREF except for only one who had reducing body myopathy due to a mutation in *FHL1*, without mutation in exon 343 of *TTN*. Although we judged this case as having necklace CBs retrospectively, CBs in this case are smaller in size and scattered in the subsarcolemmal region in muscle fibres, giving an appearance different from typical necklace CBs in HMREF (online supplementary figure S1), suggesting that the specificity of necklace CBs could be substantially 100%. In addition, muscle pathology of this patient showed typical reducing bodies in scattered fibres on MAG stain without substrate, and thus differential diagnosis between reducing body myopathy and HMREF was not a problem in practise.

Interestingly, even in three patients with HMREF without typical necklace CBs, CBs are aligned in the subsarcolemmal regions in muscle fibres, albeit they do not encompass more than half of the myofibre circumference (online supplementary figure S2), suggesting that this unique subsarcolemmal alignment pattern is likely to be related to the dysfunction of titin due to exon 343 mutations although the detailed mechanism is still unknown.

On electron microscopy (EM), CBs in the patients differ slightly from typical CBs seen in other various diseases. While typical CBs consists of a core with electron density similar to Z line,²¹ the CBs in HMREF show lower density. Furthermore, thin filaments, which compose a halo of typical CBs, are rarely seen around the CBs. Interestingly, the sarcomeric disarrangement appears to progress in order of figure 2A, C, suggesting a possibility that this sarcomeric disarrangement may ultimately produce the CBs.

Several groups reported that CBs in HMREF are reactive to antibodies to myofibrillar proteins including myotilin, α B-crystallin, actin (phalloidin), filamin C, dystrophin, and γ -sarcoglycan, but not for titin on immunohistochemical analysis.^{11 12 14 19} Although similar findings were obtained in our observation (data not shown), the pathophysiological significance of CBs in HMREF has still not been elucidated.

We found four novel variants in exon 343 of *TTN* including three heterozygous missense mutations [g.284702G>A (p.C31712Y), g.284938G>C (p.G31791R) and g.284939G>T (p.G31791V)], and a heterozygous deletion variant [g.284913_284921del (p.R31783_V31785del)]. These variants were not described in any of the publically available databases. Mutated amino acids are highly conserved among species. Also

Table 4 Sensitivity, specificity, and positive predictive value of laboratory findings for HMREF

	Respiratory disturbance in the ambulant stage	Selective affected semitendinosus muscles on muscle imaging	Necklace CBs on muscle pathology
Sensitivity	88% (14/16)	93% (14/15)	82% (14/17)
Specificity	94% (81/86)	NA	99% (169/170)
PPV	74%	NA	93%

At the time of muscle biopsy.

Respiratory disturbance: <80% of %VC or >45 mm Hg of PaCO₂. PPVs were calculated by the HMREF prevalence of 9.1% in the MFM cohort.

CB, cytoplasmic body; HMREF, hereditary myopathy with early respiratory failure; MFM, myofibrillar myopathy; NA, not available, PPV, positive predictive value; VC, vital capacity.

Table 5 Mutations in the FN3 119 domain of A-band in *TTN* in HMERF

DNA change	Amino acid change	Origin	Family	Reference
g.284693C>G	p.P31709R (p.P30068R)	French		3
g.284701T>C	p.C31712R (p.C30071R)	Swedish, British, Finnish, Italian, Spanish, Argentinian (European ancestry), East Indian, Japanese	A, B, C, D, E, F, G, H, I	2, 3, 11, 12, 14
g.284702G>A	p.C31712Y (p.C30071Y)	Japanese	J	*
g.284752T>C	p.W31729R (p.W30088R)	British		12
g.284754G>C	p.W31729C (p.W30088C)	German		12
g.284753G>T	p.W31729L (p.W30088L)	Japanese		13
g.284762C>T	p.P31732L (p.P30091 L)	Italian, French, British, Portuguese, Swedish		11, 12, 15, 16, 17
g.284913_284921del	p.R31783_V31785del (p.R30142_V30144del)	Japanese	N	*
g.284925C>G	p.N31786K (p.N30145 K)	British		11
g.284939G>A	p.G31791D (p.G30150D)	American (European ancestry), Japanese	K	14
g.284938G>C	p.G31791R (p.G30150R)	Japanese	L	*
g.284939G>T	p.G31791V (p.G30150V)	Japanese	M	*

*Possible novel mutation. Titin reference: ENST00000589042 and ENST00000591111, a former transcript, inside the brackets. HMERF, hereditary myopathy with early respiratory failure.

the variants were predicted to be pathogenic by the plural prediction software programs. Furthermore, in single-base substitutions, other types of substitutions of the same amino acids (p.C31712R and p.G31791D) have already been reported in other families with HMERF (table 5).^{2 3 11 12 14} Thus, although segregation analysis was not possible, the variants are highly likely to be pathogenic.

Previous reports suggested that HMERF might not be extremely rare in Caucasian populations.^{11 12} In UK, in patients with HMERF with p.C31712R (p.C30071R, based on ENST00000591111), mutation in exon 343 of *TTN* was identified in 5.5% of the MFM cohort.¹¹ Patients have also been identified in Asian populations including Japanese and Indian, suggesting that patients with HMERF are likely to be distributed worldwide.^{13 14 22} Here, we confirmed the presence of patients with HMERF in Japan. Furthermore, among all the 175 MFM families in our Japanese cohort, 14 families (8%) had HMERF with mutations in the exon 343 of *TTN*, which renders *TTN* the most frequent causative gene for MFM in our cohort although there still remains a possibility that there may be an undisclosed major causative gene as causative mutations have not been identified in more than 60% of the MFM families.

Clinical features of participants with HMERF described in this study coincide with those in previous reports for most parts: affected individuals usually present with predominant distal leg muscle weakness followed by chronic respiratory failure.^{1-3 11-14} Interestingly, dysphagia was seen in 4 of the 17, which was rarely described in the literature.¹³ Dysphagia seems to be mostly mild, but was severe in one patient, who required tube feeding.

Skeletal muscle imaging has been reported to show preferential involvement of semitendinosus, obturator, sartorius, gracilis, iliopsoas muscles and anterior compartment of lower legs, suggesting such imaging findings are useful for the diagnosis of HMERF.^{3 11 12 19} Particularly, selective involvement of semitendinosus muscles is commonly observed. Our study showed a sensitivity of 93%, which is compatible with 95–100% reported by previous studies.^{3 12} Unfortunately, skeletal muscle imaging was not available in many of our patients with MFM other than HMERF, and thus it was impossible to calculate the specificity and PPV of the selective involvement of semitendinosus muscles. However, it may not be so specific since such finding was observed also in other MFMs caused by mutations in *DES*, *CRYAB* and *MYOT*.^{23 24}

In conclusion, the necklace CB is a useful pathological marker in the diagnosis of HMERF. When muscle pathology shows necklace CBs, sequencing the FN3 119 domain of the A-band in *TTN* should be considered.

Author affiliations

- ¹Department of Clinical Development, Translational Medical Center, National Center of Neurology and Psychiatry (NCNP), Tokyo, Japan
- ²Department of Neuromuscular Research, National Institute of Neuroscience, NCNP, Tokyo, Japan
- ³Department of Education, Interdisciplinary Graduate School of Medicine and Engineering, University of Yamanashi, Yamanashi, Japan
- ⁴Department of Neurophysiology, Tokyo Medical University, Tokyo, Japan
- ⁵Department of Neurology, National Center Hospital, NCNP, Tokyo, Japan
- ⁶Department of Neurology, Japanese Red Cross Society, Wakayama Medical Center, Wakayama, Japan
- ⁷Institute of Clinical Research/Department of Neurology, National Hospital Organization Higashisaitama Hospital, Saitama, Japan
- ⁸Department of Neurology, National Hospital Organization Toneyama National Hospital, Osaka, Japan
- ⁹Department of Neurology, Keio University School of Medicine, Tokyo, Japan
- ¹⁰Department of Neurology, Osaka Red Cross Hospital, Osaka, Japan
- ¹¹Department of Neurology, Graduate School of Medicine, Kyoto University, Kyoto, Japan
- ¹²Department of Neurology, Institute of Brain Science, Hirosaki University Graduate School of Medicine, Aomori, Japan
- ¹³Department of Neurology, Dokkyo Medical University, Tochigi, Japan
- ¹⁴Department of Neurology, Nagoya University Graduate School of Medicine, Nagoya, Japan
- ¹⁵Department of Neurology, National Hospital Organization Maizuru Medical Center, Kyoto, Japan
- ¹⁶Department of Neurology, Neurological Institute, Graduate School of Medical Sciences, Kyushu University, Fukuoka, Japan

Acknowledgements The authors thank Ms Kaoru Tatezawa, Ms Yoriko Kojima, Ms Kazu Iwasawa, Mr Takao Uchikai, and Ms Kanako Goto in NCNP for their technical assistance.

Contributors AU was involved in the conceptualisation and design of the study, data analysis and interpretation, literature review and drafting the manuscript. YKH was involved in the conceptualisation and design of the study, data analysis and interpretation, and manuscript revision for intellectual content. YO, MM-Y, MK, MM, MK, KO, TM, SS, YT, TK, TK, YI, NK, SY, RY, and JK were involved in the collection of clinical data. SM and SN were involved in the data interpretation (molecular data) and manuscript revision for intellectual content. lK.N was involved in the supervision of pathological analysis and interpretation and manuscript revision for intellectual content. lC.N was involved in the supervision of all aspects, including study design, data analysis and interpretation, and manuscript preparation.

Funding This study was supported partly by JSPS KAKENHI Grant Number of 24659437; partly by Research on Rare and Intractable Diseases, Comprehensive Research on Disability Health and Welfare and Applying Health Technology from the Ministry of Health, Labour and Welfare of Japan; and partly by Intramural Research Grant 23-5 and 26-8 for Neurological and Psychiatric Disorders of NCNP.

Competing interests None.

Ethics approval Ethical Committee of National Center of Neurology and Psychiatry.

Provenance and peer review Not commissioned; externally peer reviewed.

REFERENCES

- Edström L, Thornell LE, Albo J, *et al.* Myopathy with respiratory failure and typical myofibrillar lesions. *J Neurol Sci* 1990;96:211–28.
- Ohlsson M, Hedberg C, Brådvik B, *et al.* Hereditary myopathy with early respiratory failure associated with a mutation in A-band titin. *Brain* 2012;135:1682–94.
- Pfeffer G, Elliott HR, Griffin H, *et al.* Titin mutation segregates with hereditary myopathy with early respiratory failure. *Brain* 2012;135:1695–713.
- Haravuori H, Mäkelä-Bengs P, Udd B, *et al.* Assignment of the tibial muscular dystrophy locus to chromosome 2q31. *Am J Hum Genet* 1998;62:620–6.
- Hackman P, Vihola A, Haravuori H, *et al.* Tibial muscular dystrophy is a titinopathy caused by mutations in TTN, the gene encoding the giant skeletal-muscle protein titin. *Am J Hum Genet* 2002;71:492–500.
- Carmignac V, Salih MA, Quijano-Roy S, *et al.* C-terminal titin deletions cause a novel early-onset myopathy with fatal cardiomyopathy. *Ann Neurol* 2007;61:340–51.
- Gerull B, Gramlich M, Atherton J, *et al.* Mutations of TTN, encoding the giant muscle filament titin, cause familial dilated cardiomyopathy. *Nat Genet* 2002;30:201–4.
- Itoh-Satoh M, Hayashi T, Nishi H, *et al.* Titin mutations as the molecular basis for dilated cardiomyopathy. *Biochem Biophys Res Commun* 2002;291:385–93.
- Herman DS, Lam L, Taylor MRG, *et al.* Truncations of titin causing dilated cardiomyopathy. *New Eng J Med* 2012;366:619–28.
- Satoh M, Takahashi M, Sakamoto T, *et al.* Structural analysis of the titin gene in hypertrophic cardiomyopathy: identification of a novel disease gene. *Biochem Biophys Res Commun* 1999;262:411–17.
- Pfeffer G, Barresi R, Wilson LJ, *et al.* Titin founder mutation is a common cause of myofibrillar myopathy with early respiratory failure. *J Neurol Neurosurg Psychiatry* 2014;85:331–8.
- Palmio J, Evilä A, Chapon F, *et al.* Hereditary myopathy with early respiratory failure: occurrence in various populations. *J Neurol Neurosurg Psychiatry* 2014;85:345–53.
- Izumi R, Niihori T, Aoki Y, *et al.* Exome sequencing identifies a novel TTN mutation in a family with hereditary myopathy with early respiratory failure. *J Hum Genet* 2013;58:259–66.
- Toro C, Olivé M, Dalakas MC, *et al.* Exome sequencing identifies titin mutations causing hereditary myopathy with early respiratory failure (HMERF) in families of diverse ethnic origins. *BMC Neurol* 2013;13:29.
- Vasli N, Böhm J, Le Gras S, *et al.* Next generation sequencing for molecular diagnosis of neuromuscular diseases. *Acta Neuropathol* 2012;124:273–83.
- Hedberg C, Melberg A, Dahlbom K, *et al.* Hereditary myopathy with early respiratory failure is caused by mutations in the titin FN3 119 domain. *Brain* 2014;137(Pt 4):e270.
- Lange S, Edström L, Udd B, *et al.* Reply: Hereditary myopathy with early respiratory failure is caused by mutations in the titin FN3 119 domain. *Brain* 2014;137(Pt 6):e279.
- Schröder R, Schoser B. Myofibrillar Myopathies: A clinical and myopathological Guide. *Brain Pathol* 2009;19:483–92.
- Tasca G, Mirabella M, Broccolini A, *et al.* An Italian case of hereditary myopathy with early respiratory failure (HMERF) not associated with the titin kinase domain R279W mutation. *Neuromuscul Disord* 2010;20:730–4.
- Cho A, Hayashi YK, Momma K, *et al.* Mutation Profile of the GNE gene in Japanese patients with distal myopathy with rimmed vacuoles (GNE myopathy). *J Neurol Neurosurg Psychiatry*. 2014;85:914–17.
- Macdonald RD, Engel AG. The cytoplasmic body: another structural anomaly of the Z disk. *Acta Neuropathol* 1969;14:99–107.
- Uruha A, Nishino I. Think worldwide: hereditary myopathy with early respiratory failure (HMERF) may not be rare. *J Neurol Neurosurg Psychiatry* 2014;85:248.
- Fisher D, Kley RA, Stratch K, *et al.* Distinct muscle imaging patterns in myofibrillar myopathies. *Neurology* 2008;71:758–65.
- Wattjes MP, Kley RA, Fischer D. Neuromuscular imaging in inherited muscle diseases. *Eur Radiol* 2010;20:2447–60.



Necklace cytoplasmic bodies in hereditary myopathy with early respiratory failure

Akinori Uruha, Yukiko K Hayashi, Yasushi Oya, et al.

J Neurol Neurosurg Psychiatry published online September 24, 2014
doi: 10.1136/jnnp-2014-309009

Updated information and services can be found at:
<http://jnnp.bmj.com/content/early/2014/09/24/jnnp-2014-309009.full.html>

These include:

Data Supplement

"Supplementary Data"

<http://jnnp.bmj.com/content/suppl/2014/09/24/jnnp-2014-309009.DC1.html>

References

This article cites 24 articles, 8 of which can be accessed free at:

<http://jnnp.bmj.com/content/early/2014/09/24/jnnp-2014-309009.full.html#ref-list-1>

P<P

Published online September 24, 2014 in advance of the print journal.

Email alerting service

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Topic Collections

Articles on similar topics can be found in the following collections

[Muscle disease](#) (230 articles)

[Musculoskeletal syndromes](#) (486 articles)

[Neuromuscular disease](#) (1171 articles)

Advance online articles have been peer reviewed, accepted for publication, edited and typeset, but have not yet appeared in the paper journal. Advance online articles are citable and establish publication priority; they are indexed by PubMed from initial publication. Citations to Advance online articles must include the digital object identifier (DOIs) and date of initial publication.

To request permissions go to:

<http://group.bmj.com/group/rights-licensing/permissions>

To order reprints go to:

<http://journals.bmj.com/cgi/reprintform>

To subscribe to BMJ go to:

<http://group.bmj.com/subscribe/>

REVIEW

Ullrich congenital muscular dystrophy: clinicopathological features, natural history and pathomechanism(s)

Takahiro Yonekawa,^{1,2} Ichizo Nishino^{1,3}¹Department of Neuromuscular Research, National Institute of Neuroscience, National Center of Neurology and Psychiatry (NCNP), Kodaira, Tokyo, Japan²Department of Child Neurology, National Center Hospital, NCNP, Kodaira, Tokyo, Japan³Department of Clinical Development, Translational Medical Center, NCNP**Correspondence to**Dr Ichizo Nishino, Department of Neuromuscular Research, National Institute of Neuroscience, NCNP, 4-1-1, Ogawa-Higashicho, Kodaira, Tokyo 187 8502, Japan; nishino@ncnp.go.jp

Received 15 April 2014

Revised 12 May 2014

Accepted 25 May 2014

Published Online First

17 June 2014

ABSTRACT

Collagen VI is widely distributed throughout extracellular matrices (ECMs) in various tissues. In skeletal muscle, collagen VI is particularly concentrated in and adjacent to basement membranes of myofibers. Ullrich congenital muscular dystrophy (UCMD) is caused by mutations in either *COL6A1*, *COL6A2* or *COL6A3* gene, thereby leading to collagen VI deficiency in the ECM. It is known to occur through either recessive or dominant genetic mechanism, the latter most typically by *de novo* mutations. UCMD is well defined by the clinicopathological hallmarks including distal hyperlaxity, proximal joint contractures, protruding calcanei, scoliosis and respiratory insufficiency. Recent reports have depicted the robust natural history of UCMD; that is, loss of ambulation by early teenage years, rapid decline in respiratory function by 10 years of age and early-onset, rapidly progressive scoliosis. Muscle pathology is characterised by prominent interstitial fibrosis disproportionate to the relative paucity of necrotic and regenerating fibres. To date, treatment for patients is supportive for symptoms such as joint contractures, respiratory failure and scoliosis. There have been clinical trials based on the theory of mitochondrion-mediated myofiber apoptosis or impaired autophagy. Furthermore, the fact that collagen VI producing cells in skeletal muscle are interstitial mesenchymal cells can support proof of concept for stem cell-based therapy.

INTRODUCTION

Collagen VI is an important component of the ECM of skeletal muscle and is involved in maintaining tissue integrity by providing a structural link between different ECM molecules and in promoting adhesion,^{1,2} proliferation,³ migration⁴ and survival⁵ of various cell types. Collagen VI-related myopathies are the hereditary myopathies caused by mutations in either *COL6A1*, *COL6A2* or *COL6A3* gene, each encoding a subunit of collagen VI. Patients have the clinicopathological features of a muscle disorder as well as of a connective tissue disorder, although the link between this defect of ECM and phenotype remains to be fully elucidated.

Recent advance in molecular biology has evolved the aetiological definition of collagen VI-related myopathies; these myopathies are known to encompass a clinical continuum with Ullrich congenital muscular dystrophy (UCMD) and Bethlem myopathy (BM) at each end of the spectrum, originally described separately.^{6–8} Intermediate phenotypes, named as mild UCMD or severe BM, have been

known but less well defined as there is currently no clear-cut boundary between two major phenotypes. In addition, it should be noted that genotype-phenotype correlation is very difficult to establish; for example, both extremes of the clinical spectrum are seen in patients with p.Gly284Arg mutation in the *COL6A1* gene, the most commonly observed mutation, while half had an intermediate phenotype.⁹ In this context, several researchers have proposed the clinical stratification of patients with collagen VI-related myopathies (figure 1A).^{10–12}

The hallmarks of UCMD include marked distal joint hyperlaxity associated with proximal joint contractures, a rigid spine and normal intelligence. Furthermore, children presenting UCMD phenotype have been referred to as having ‘early severe’ or ‘moderately progressive’ course of early-onset collagen VI-related myopathies according to maximal motor ability and disease progression.^{10–12} Thus, UCMD is relatively well defined as compared with BM or intermediate phenotypes.

CLINICAL PICTURE

In 1930, Otto Ullrich described two boys with an unusual congenital myopathy characterised by muscle weakness and wasting, marked distal joint looseness and contracture of the proximal joints since birth or early infancy and termed this new condition “Kongenitale, atonisch-skelerotische Muskeldystrophie, ein weiterer Typus der heredo-degenerativen Erkrankungen des neuromuskulären Systems”.^{6,7} Subsequent publications confirmed a likely autosomal-recessive inheritance and a recognisable pattern of disease.¹³ The diagnostic clinical and molecular criteria for UCMD have been proposed by the European Neuromuscular Centre.¹⁴

Epidemiology

UCMD is the second most common congenital muscular dystrophy (CMD) after CMD with laminin $\alpha 2$ deficiency (also known merosin-deficient CMD; or MDC1A) in Europe,¹⁵ after Fukuyama CMD in Japan¹⁶ and after α -dystroglycanopathies in Australia.¹⁷ The prevalence of UCMD is reported to be 1.3 per million in Northern England.¹⁸

Perinatal features and development

Prenatal movements might be reduced in fetuses with UCMD.¹⁹ Some patients have congenital hip dislocation, torticollis and transient kyphotic deformity.^{19,20} Multiple joint contractures may be evident at birth, affecting the elbows, knees, spine



CrossMark

To cite: Yonekawa T, Nishino I. *J Neurol Neurosurg Psychiatry* 2015;**86**:280–287.